Intravesical Gemcitabine For Superficial Bladder Cancer

Share this content:

SAN FRANCISCO—Intravesical gemcitabine may be a safe and effective treatment for superficial bladder cancer, data suggest.

 

Australian investigators tested the treatment in a Phase II trial that enrolled 54 patients. Intravesical gemcitabine (2000 mg) was administered one hour every week for six consecutive weeks. Of 44 patients evaluable for response, 16 (36%) had a complete response (no evidence of tumor, negative cytology) and 17 (39%) had a partial response (positive cytology with negative cystocscopy or reduced tumor bulk). Seven patients (16%) had stable disease and four (9%) progressed.

 

Toxicities were mild and urinary; no systemic or hematologic toxicity greater than grade 1 occurred.

 

Findings were reported here at the 2008 Genitourinary Cancers Symposium.

You must be a registered member of Renal and Urology News to post a comment.